Huyuan Yang
About
Huyuan Yang is a scholar working on Molecular Biology, Hematology and Oncology.
According to data from OpenAlex, Huyuan Yang has authored 34 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Molecular Biology, 11 papers in Hematology and 9 papers in Oncology. Recurrent topics in Huyuan Yang's work include Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Huyuan Yang is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Protein Degradation and Inhibitors (5 papers) and Chronic Lymphocytic Leukemia Research (4 papers). Huyuan Yang collaborates with scholars based in United States, Canada and United Kingdom. Huyuan Yang's co-authors include Neeraj Gupta, Maria Rosario, Quynh-Van Tran, Brian G. Feagan, Robert Berman, Michael J. Hanley, Asit Parikh, Karthik Venkatakrishnan, Silvio Danese and Vishal Kukreti and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Cancer Research.
In The Last Decade
Huyuan Yang
33 papers receiving 648 citations
Peers
Huyuan Yang
William E. Pullman United States
Denise Lowe United States
Masao Yukioka Japan
Julia Driesen Germany
V. Spencer United States
C. Justin Van De Wiele United States
Tatiana Raskovalova France
A. Bennet France
Mi‐Jung Kim South Korea
Brian Kornblit Denmark
Citations per year, relative to Huyuan Yang Huyuan Yang (= 1×)
peers
William E. Pullman
Countries citing papers authored by Huyuan Yang
Since
Specialization
Citations
This map shows the geographic impact of Huyuan Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huyuan Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huyuan Yang more than expected).
Fields of papers citing papers by Huyuan Yang
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Huyuan Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huyuan Yang. The network helps show where Huyuan Yang may publish in the future.
Co-authorship network of co-authors of Huyuan Yang
This figure shows the co-authorship network connecting the top 25 collaborators of Huyuan Yang. A scholar is included among the top collaborators of Huyuan Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huyuan Yang. Huyuan Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Yang, Huyuan, Kun Zhang, Xiao-Hui Wang, & Hailong Shi. (2025). Optimal energy storage and collective charging speedup in the central-spin quantum battery. Physical review. B.. 111(8).
2.
Saba, Nabil F., Tomasz Rutkowski, Massimo Di Maïo, et al.. (2024). 877P Exploratory efficacy and translational results from the safety run in of AHEAD-MERIT, a phase II trial of first line pembrolizumab plus the fixed-antigen cancer vaccine BNT113 in advanced HPV16+ HNSCC. Annals of Oncology. 35. S627–S627.
3.
Zhao, Weiguang, Yuanfang Li, Dan Zou, et al.. (2023). Efficacy and safety of Axicabtagene ciloleucel (Axi‐cel) for the treatment of relapse/refractory non‐Hodgkin lymphoma: First real‐world data in Chinese population. Hematological Oncology. 41(S2). 457–458.
4.
Baranda, Joaquina, Michael S. Gordon, Aparna R. Parikh, et al.. (2022). Abstract CT134: Phase 1, first-in-human, dose-escalation, safety, pharmacokinetic (PK), and pharmacodynamic study of oral TP-0184, an activin receptor-like kinase-2 (ALK2) inhibitor, in patients (pts) with advanced solid tumors (ASTs). Cancer Research. 82(12_Supplement). CT134–CT134.
5.
Yang, Huyuan, et al.. (2019). Intratumoral polymorphism of peroxisome proliferator-activated receptor delta -87 T>C in colorectal cancer. Neoplasma. 66(4). 609–618.
6.
Dimopoulos, Meletios Α., Sebastian Grosicki, W Wiktor-Jędrzejczak, et al.. (2018). All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. European Journal of Cancer. 106. 89–98.
7.
Wu, Xiaohua, Jun Wang, Qi Zhou, et al.. (2018). Pamiparib, a novel PARP 1/2 inhibitor, monotherapy for gBRCAm patients with recurrent ovarian, fallopian, and primary peritoneal cancer: An open-label, multicenter, phase II trial in China. Annals of Oncology. 29. viii356–viii356.
8.
Sanchorawala, Vaishali, Giovanni Palladini, Vishal Kukreti, et al.. (2017). A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood. 130(5). 597–605.
9.
Gupta, Neeraj, Huyuan Yang, Michael J. Hanley, et al.. (2017). Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma: Clinical and Model-Based Analyses. Targeted Oncology. 12(5). 643–654.
10.
Almhanna, Khaldoun, David Wright, T. Macarulla Mercadé, et al.. (2017). A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing guanylyl cyclase C. Investigational New Drugs. 35(5). 634–641.
11.
Bang, Yung‐Jue, Toshimi Takano, Chia‐Chi Lin, et al.. (2017). TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study. Cancer Research and Treatment. 50(2). 398–404.
12.
Rosario, Maria, Jonathan French, Nathanael L. Dirks, et al.. (2017). Exposure–efficacy Relationships for Vedolizumab Induction Therapy in Patients with Ulcerative Colitis or Crohn’s Disease. Journal of Crohn s and Colitis. 11(8). 921–929.
13.
Gupta, Neeraj, Michael J. Hanley, R. Donald Harvey, et al.. (2016). A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end‐stage renal disease requiring haemodialysis. British Journal of Haematology. 174(5). 748–759.
14.
Reinisch, Walter, James D. Lewis, Themistocles Dassopoulos, et al.. (2015). DOP042. Clinical response and remission with vedolizumab across a range of baseline fecal calprotectin levels in ulcerative colitis: Results from GEMINI 1. Journal of Crohn s and Colitis. 9(suppl 1). S47–S47.
15.
Gupta, Neeraj, Yeow Tee Goh, Chang‐Ki Min, et al.. (2015). Pharmacokinetics and safety of ixazomib plus lenalidomide–dexamethasone in Asian patients with relapsed/refractory myeloma: a phase 1 study. Journal of Hematology & Oncology. 8(1). 103–103.
16.
Rosario, Maria, Irving H. Fox, Catherine Milch, et al.. (2013). P-140 Pharmacokinetic/Pharmacodynamic Relationship and Immunogenicity of Vedolizumab in Adults with Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 19. S80–S80.
17.
Steffens, David C., J. Craig Nelson, James M. Eudicone, et al.. (2010). Efficacy and safety of adjunctive aripiprazole in major depressive disorder in older patients: a pooled subpopulation analysis. International Journal of Geriatric Psychiatry. 26(6). 564–572.
18.
Fava, Maurizio, Stephen R. Wisniewski, Michael E. Thase, et al.. (2009). Metabolic Assessment of Aripiprazole as Adjunctive Therapy in Major Depressive Disorder. Journal of Clinical Psychopharmacology. 29(4). 362–367.
19.
Thase, Michael E., Madhukar H. Trivedi, J. Craig Nelson, et al.. (2008). Examining the Efficacy of Adjunctive Aripiprazole in Major Depressive Disorder. The Primary Care Companion to The Journal of Clinical Psychiatry. 10(6). 440–447.
20.
Trivedi, Madhukar H., Michael E. Thase, Maurizio Fava, et al.. (2008). Adjunctive Aripiprazole in Major Depressive Disorder. The Journal of Clinical Psychiatry. 69(12). 1928–1936.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by William E. Pullman Breakdown of academic impact, for papers by Denise Lowe Breakdown of academic impact, for papers by Masao Yukioka Breakdown of academic impact, for papers by Julia Driesen Breakdown of academic impact, for papers by V. Spencer Breakdown of academic impact, for papers by C. Justin Van De Wiele Breakdown of academic impact, for papers by Tatiana Raskovalova Breakdown of academic impact, for papers by A. Bennet Breakdown of academic impact, for papers by Mi‐Jung Kim Breakdown of academic impact, for papers by Brian Kornblit